/
Biological products, (no diagnostic substances) company · DE · FY ends Dec · Revenue $88M · -203.47% margin · -$129M FCF
$9.53
+$0.26 (+2.80%)
Price from 2 days ago
The business is unprofitable at the operating level (-187.24% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 230194.6% YoY with margins expanding 507491.1pp.
Negative free cash flow of -$110M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$88M
▲ +230194.6% YoY
Net Income (TTM)
-$161M
▲ +12.9% YoY
Op. Margin
-203.47%
▲ +507491.1pp YoY
ROIC
-30.92%
▲ +10.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$129M
▲ +20.8% YoY
Op. Cash Flow (TTM)
-$129M
▲ +18.9% YoY
Net Debt
-$370M
Net Cash Position
Cash & Equiv.
$391M
5Y CAGR: +44.3%
Continue Research